Novo Nordisk and Vivtex Forge Up to $2.1 Billion Deal for Oral Obesity Drugs

• The deal includes an undisclosed upfront payment plus milestone payments and royalties, totaling up to $2.1 billion
• Vivtex's platform uses gut-screening tests, delivery technologies, and AI tools to convert biologic drugs typically given as injections into oral pill forms
• Novo Nordisk launched the world's first oral obesity drug (Wegovy pill) in the U.S. in January 2026, and already markets injectable GLP-1 drugs Wegovy, Ozempic, and oral diabetes drug Rybelsus

Novo Nordisk and Vivtex Forge $2.1 Billion Oral Obesity Drug Partnership

Danish pharmaceutical giant Novo Nordisk has entered a strategic partnership with privately held U.S.-based Vivtex Corp, valued at up to $2.1 billion, to develop next-generation oral medications for obesity and diabetes. The deal was announced on February 25th.

Deal Structure:

Under the agreement, Novo Nordisk will provide an undisclosed upfront payment, plus milestone payments and royalties on future product sales. Vivtex will license its proprietary oral drug-delivery technology, while Novo Nordisk assumes responsibility for global development and commercialization.

Technology Focus:

The partnership aims to transform biologic drugs—typically administered via injection—into oral formulations by enhancing gut absorption. Vivtex's platform integrates gut-screening tests, advanced delivery technologies, and artificial intelligence tools to enable biologic drugs to function effectively as pills.

Market Context:

Novo Nordisk currently dominates the GLP-1 drug market with blockbuster treatments including Wegovy and Ozempic for obesity and type 2 diabetes, along with Rybelsus, an oral diabetes medication. In January 2026, the company launched the world's first oral obesity drug—a pill version of Wegovy—in the United States.

Market Implications:

This collaboration strengthens Novo Nordisk's leadership position in the rapidly expanding obesity and diabetes treatment market. The shift toward oral formulations addresses a significant patient preference over injections, potentially expanding market reach and improving treatment adherence. The substantial deal value underscores the pharmaceutical industry's recognition that oral delivery platforms represent the next frontier in biologic drug development, with significant commercial potential in the multi-billion-dollar metabolic disease sector.